Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR183 | P32249 | 8/20 | 0.51 |
| ▸ | RET | P07949 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | NNMT | P40261 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | TACR3 | P29371 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20153163 | 0.87 | GPR183 (0.53) | GPR183RETHRH3NNMTKCNH2 | |
| SCHEMBL21159105 | 0.86 | GPR183 (0.52) | GPR183RETNNMTKCNH2GABRA5 | |
| SCHEMBL20070913 | 0.86 | GPR183 (0.52) | GPR183RETNNMTKCNH2GABRA5 | |
| SCHEMBL23555335 | 0.85 | GPR183 (0.52) | GPR183RETNNMTKCNH2GABRA5 | |
| SCHEMBL20148743 | 0.84 | GPR183 (0.51) | GPR183RETHRH3NNMTKCNH2 | |
| SCHEMBL20153275 | 0.82 | ALDH1A1 (0.54) | RETKDM4EALDH1A1LMNA | |
| SCHEMBL20160527 | 0.76 | ALDH1A1 (0.48) | RETHRH3ALDH1A1LMNA | |
| SCHEMBL22031223 | 0.76 | HRH3 (0.71) | GPR183HRH3NNMTKCNH2GABRA5 | |
| SCHEMBL20160528 | 0.76 | OPRM1 (0.48) | RETKDM4E | |
| SCHEMBL30374831 | 0.75 | GPR183 (0.82) | GPR183KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134702-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134702-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | GPR183 1682/4885RET 1/4885HRH3 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.